A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

Healthy Clinical Trial

Official title:

An Open-label, Multi-center, Single-dose, Parallel-group Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04494269
• Other study ID #: IN_APA_116
• Status: Recruiting
• Phase: Phase 1
• Start date: September 8, 2020
• Est. completion date: December 2023

Study information

• Verified date: July 2020
• Source: HK inno.N Corporation
• Contact: Youngshin Keum, R.Ph, Pharm.D
• Phone: +82-2-6477-0204
• Email: ys.keum[@]inno-n.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to compare the pharmacokinetic and safety of tegoprazan following single oral dose in subjects with hepatic impairment versus healthy control.

Description:

[Pharmacokinetic Assessment]

• Measurements

• Tegoprazan and desmethyl tegoprazan (M1) in blood and urine

• Endpoints

• Primary endpoints: AUClast and Cmax of tegoprazan and M1

• Secondary endpoints: CL/F, t1/2, AUCinf, and fu of tegoprazan; CLrenal and Ae of tegoprazan and M1

[Safety Assessment]

• Adverse events (AEs)

• Clinical laboratory tests

• Vital sign

• Physical examination

• Electrocardiogram (ECG)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: December 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 70 Years

Eligibility

[Healthy Control Group]

Inclusion Criteria:

• Subjects aged 19 to 70(inclusive) years at the time of signing the informed consent form.

• Subjects with a body weight of = 50 kg and = 90 kg at screening.

• Subjects with AST, ALT, and ALP levels of = 1.5 × upper limit of the normal reference range (ULN) with total bilirubin < 2 mg/dL and PT (INR) < 1.7 at screening.

• Subjects who have no chronic disease or any congenital disease within the last 5 years and no pathological symptoms or findings as a result of an internal examination

• Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the investigational product(IP).

Exclusion Criteria:

• Subjects who show symptoms of acute disease at the time of screening.

• Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.

• Subjects with history or current evidence of gastrointestinal or hepatobiliary disease which may affect PK evaluation of the IP.

• Subjects with history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).

• Subjects with systolic blood pressure (BP) of < 90 mmHg or > 160 mmHg, or diastolic BP of < 50 mmHg or > 100 mmHg at screening.

• Subjects who have received medication or food which may significantly affect absorption, distribution, metabolism, or elimination of study drug within 7 days prior to scheduled study treatment.

• Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.

• Subjects who have donated whole blood within 60 days prior to the scheduled study treatment, or has donated blood components or received transfusion within 30 days prior to scheduled study treatment.

• Subjects who are unable to use a medically acceptable contraceptive method throughout the study.

• Subjects who are determined ineligible for study participation by the investigator for other reasons.

[Subjects with Hepatic Impairment]

Inclusion Criteria:

• Subjects with chronic liver disease who meet any of the followings:

• Chronic Hepatitis B;

• Chronic Hepatitis C;

• Alcoholic liver disease;

• Non-alcoholic fatty liver disease; or

• Liver fibrosis and cirrhosis.

• Subjects aged 19 to 70 years (inclusive) at the time of signing the informed consent form.

• Subjects with body weight of = 50 kg and = 90 kg with a BMI of = 18.0 kg/m2 and = 30 kg/m2 at screening.

• Subjects who meet any of following criteria:

• AST, ALT, or ALP level > 1.5 × ULN at screening;

• Total bilirubin = 2 mg/dL at screening; or

• PT (INR) = 1.7 at screening.

• Subjects who provide voluntary written informed consent to study participation after being informed of detailed explanation and fully understanding study objectives, procedures and characteristics of the IP.

Exclusion Criteria:

• Subjects who show symptoms of acute disease at the time of screening.

• Subjects with any clinically significant disease related to ongoing cardiovascular problem, respiratory system, kidney, endocrine system, hematologic, central nervous system, mental health disorder, or malignant tumor.

• Subjects with a history or current evidence of gastrointestinal disease which may affect PK evaluation for the IP.

• Subjects who have clinical changes to an estimated level that may affect PK evaluation of the study drug within 30 days prior to the scheduled dosing date.

• Changes in existing medications including dosage regimen within 30 days prior to the scheduled dosing date.

• Subjects with prior history or current evidence of clinically significant hypersensitivity to drugs containing any ingredient of proton pump inhibitors or potassium-competitive acid blockers and other drugs (such as aspirin and antibiotics).

• Systolic BP of < 90 mmHg or > 160 mmHg, or diastolic BP of < 50 mmHg or > 100 mmHg at screening.

• Any concomitant medications or foods which may significantly affect absorption, distribution, metabolism, or elimination of the study drug within 7 days prior to the scheduled dosing date.

• Subjects who have participated in any other clinical study or bioequivalence study and received investigational agent within 180 days prior to scheduled study treatment.

• Subjects who have donated whole blood within 60 days prior to the scheduled dosing date, or have donated blood components or received transfusion within 30 days prior to the scheduled dosing date.

• Subjects who are unable to use medically acceptable contraceptive methods throughout the study.

• Subjects who are determined to be ineligible for study participation by the investigator for other reasons.

Related Conditions & MeSH terms

• Healthy
• Hepatic Impairment
• Liver Diseases

Intervention

Drug:
• Tegoprazan 50mg
Oral administration once daily

Locations

Country	Name	City	State
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	CHA Bundang Medical Center	Seongnam-si
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
HK inno.N Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic Assessment	AUClast of tegoprazan and M1	Up to 48 hours
Primary	Pharmacokinetic Assessment	Cmax of tegoprazan and M1	Up to 48 hours
Secondary	Pharmacokinetic Assessment	CL/F of tegoprazan	Up to 48 hours
Secondary	Pharmacokinetic Assessment	t½ of tegoprazan	Up to 48 hours
Secondary	Pharmacokinetic Assessment	AUCinf of tegoprazan	Up to 48 hours
Secondary	Pharmacokinetic Assessment	fu of tegoprazan	Up to 48 hours
Secondary	Pharmacokinetic Assessment	CLrenal of tegoprazan and M1	Up to 48 hours
Secondary	Pharmacokinetic Assessment	Ae of tegoprazan and M1	Up to 48 hours